Journal Article

Amyloid-beta and tau pathologies act synergistically to induce novel disease stage-specific microglia subtypes

Cao, Tianyu, Li, Tong, Schnaar, Ronald L., Lau, Ashley J., Gonzalez-Gil, Anabel, Troncoso, Juan C., Wong, Philip C., Wei, Alice, Blackshaw, Seth, Tu, Kevin J., Ling, Jonathan P., Kim, Dong Won, Braunstein, Kerstin

2022

Overview

Background Amongst risk alleles associated with late-onset Alzheimer’s disease (AD), those that converged on the regulation of microglia activity have emerged as central to disease progression. Yet, how canonical amyloid-β (Aβ) and tau pathologies regulate microglia subtypes during the progression of AD remains poorly understood. Methods We use single-cell RNA-sequencing to profile microglia subtypes from mice exhibiting both Aβ and tau pathologies across disease progression. We identify novel microglia subtypes that are induced in response to both Aβ and tau pathologies in a disease-stage-specific manner. To validate the observation in AD mouse models, we also generated a snRNA-Seq dataset from the human superior frontal gyrus (SFG) and entorhinal cortex (ERC) at different Braak stages. Results We show that during early-stage disease, interferon signaling induces a subtype of microglia termed Early-stage AD-Associated Microglia (EADAM) in response to both Aβ and tau pathologies. During late-stage disease, a second microglia subtype termed Late-stage AD-Associated Microglia (LADAM) is detected. While similar microglia subtypes are observed in other models of neurodegenerative disease, the magnitude and composition of gene signatures found in EADAM and LADAM are distinct, suggesting the necessity of both Aβ and tau pathologies to elicit their emergence. Importantly, the pattern of EADAM- and LADAM-associated gene expression is observed in microglia from AD brains, during the early (Braak II)- or late (Braak VI/V)- stage of the disease, respectively. Furthermore, we show that several Siglec genes are selectively expressed in either EADAM or LADAM. Siglecg is expressed in white-matter-associated LADAM, and expression of Siglec - 10 , the human orthologue of Siglecg, is progressively elevated in an AD-stage-dependent manner but not shown in non-AD tauopathy. Conclusions Using scRNA-Seq in mouse models bearing amyloid-β and/or tau pathologies, we identify novel microglia subtypes induced by the combination of Aβ and tau pathologies in a disease stage-specific manner. Our findings suggest that both Aβ and tau pathologies are required for the disease stage-specific induction of EADAM and LADAM. In addition, we revealed Siglecs as biomarkers of AD progression and potential therapeutic targets.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Advertising executives / Alzheimer Disease - metabolism / Alzheimer's disease / Alzheimer’s disease (AD) / Amyloid beta-Peptides - metabolism / Amyloid-β (Aβ) / Amyloidosis / Analysis / Animal models / Animals / Biological response modifiers / Biomedical and Life Sciences / Biomedicine / Brain research / Cortex (entorhinal) / Development and progression / Disease Models, Animal / Disease Progression / Frontal gyrus / Gene expression / Genomics / Histology / Humans / Interferon / Laboratory animals / Mice / Microglia / Microglia - metabolism / Molecular Medicine / Nervous system diseases / Neurodegenerative diseases / Neurodegenerative Diseases - metabolism / Neurology / Neurosciences / Pathology / Research Article / Sialic acid-binding immunoglobulin-type lectin (Siglec) / snRNA / Substantia alba / Target marketing / Tau / Tau protein / tau Proteins - metabolism / Therapeutic targets / Transgenic animals / β-Amyloid